Roche, Epigenomics in E100 million methylation deal
This article was originally published in Clinica
Executive Summary
The deal signed this seek between Roche and Germany's Epigenomics to develop cancer diagnostic tests based on DNA methylation technologies is the largest of its kind to date. Roche has paid E4m ($4.3m) to Epigenomics at the start of a three-year collaboration, which could eventually be worth over E100m, says the Swiss company.